Celsis International has said that Nestlé's global R&D site in Konolfingen has invested in the new Celsis CellScan system for testing its milk- and cream-based products after its evaluation of available ATP based testing systems.
Celsis said Nestlé has already installed the CellScan rapid testing system into the global R&D site in Konolfingen, and Nestlé is also currently utilising Celsis' technology in several of their other sites in Germany and throughout Europe.
Celsis is a microbial testing company whose diagnostic systems detect and measure contamination, for the pharmaceutical, personal care & cosmetic and food industries.
The company claims that CellScan provides Nestlé with test results in as few as 48 hours, enabling them to release product quickly and confidently, as well as delivering significant financial savings in inventory and warehousing costs.
The company said that its CellScan system, specifically developed for the dairy industry's needs, provides high throughput screening with superior sensitivity compared to other available ATP screening product offerings on the market.
The CellScan has the ability to process up to 384 samples per hour so can turnaround samples as quickly as the largest manufacturer can produce them.
Founded by European biotech entrepreneur Sir Christopher Evans, Celsis became a Public Limited Company in 1993. Since its inception, Celsis International plc has grown from its once small headquarters in England to include offices in the US, the Netherlands, France, Germany and Belgium as well as a global network of distributors.The company specialises in rapid bacterial testing methods for the consumer product manufacturing environment.